HIV/HBV Coinfection
Coverage of the 2012 AASLD Liver Meeting
- Details
- Category: HBV Treatment
- Published on Tuesday, 13 November 2012 00:00
- Written by Liz Highleyman
HIVandHepatitis.com coverage of the 63rd Annual Meeting of the American Association for the Study of Liver Diseases (AASLD 2012) in Boston, November 9-13, 2012.
Conference highlights include treatment for hepatitis B and C, new direct-acting HCV drugs, interferon-free hepatitis C therapy, management of liver disease complications, HIV/HBV and HIV/HCV coinfection, and prevention and treatment of hepatocellular carcioma.
HIVandHepatitis.com AASLD 2012 conference section
11/13/12
Liver Meeting Highlights: New Hep C Drugs, NAFLD, Liver Cancer, Acetaminophen Toxicity, Benefits of Coffee
- Details
- Category: Hepatitis B
- Published on Monday, 12 November 2012 00:00
- Written by Liz Highleyman
The American Association for the Study of Liver Diseases Liver Meeting is the premier annual U.S. conference on 
hepatology, covering all aspects of liver disease including viral hepatitis, fatty liver, hepatocellular carcinoma, and liver transplantation. Kicking off the meeting on Saturday, AASLD President Guadalupe Garcia-Tsao offered a media overview of some highlights selected from the more than 2000 abstracts to be presented during the week.
Tenofovir Leads to HBsAg Clearance in 8% of HIV/HBV Coinfected Patients
- Details
- Category: HIV/HBV Coinfection
- Published on Tuesday, 02 October 2012 00:00
- Written by Liz Highleyman
Treatment with tenofovir (Viread) led to hepatitis B surface antigen (HBsAg) clearance -- considered the closest outcome to a cure -- in 8% of HIV positive patients with chronic hepatitis B virus (HBV) coinfection, and in a subgroup clearance was associated with CD4 T-cell count, Dutch researchers reported in the September 15, 2012, Journal of Infectious Diseases.
AASLD Liver Meeting Starts this Weekend in Boston
- Details
- Category: Hepatitis B
- Published on Friday, 09 November 2012 00:00
- Written by Liz Highleyman
The American Association for the Study of Liver Diseases (AASLD) annual Liver Meeting is underway, running November 9-13 at the Hynes Convention Center in Boston. The AASLD meeting each fall and the European Association for the Study of the Liver (EASL) International Liver Congress each spring are the premier events for presentation of the latest data on treatment for hepatitis B and C.
ICAAC 2012: Raltegravir Shows Long-term Safety and Efficacy for HIV/HCV and HIV/HBV Coinfection
- Details
- Category: HIV/Hepatitis Coinfection
- Published on Thursday, 20 September 2012 00:00
- Written by Liz Highleyman
The HIV integrase inhibitor raltegravir (Isentress) was well-tolerated and demonstrated continued effectiveness for 5 years in treatment-naive and 3 years in treatment-experienced HIV patients coinfected with hepatitis B or C, according to a poster presentation at the 52nd Interscience Conference on Antimicrobial Agents and Chemotherapy (ICAAC) last week in San Francisco.
More Articles...
- ICAAC 2012: Switching to Tenofovir in ART Regimen Suppresses Hepatitis B in HIV/HBV Coinfected
- AIDS 2012: HIV/HBV Coinfection Linked to Higher Mortality, More ART Liver Toxicity
- Hepatitis B Linked to More HIV+ Deaths than Hepatitis C, Risk High for People with AIDS
- CROI 2012: Detectable HIV Raises Risk of Incomplete Hepatitis B Suppression
Web Design and Development by